Kiora Pharmaceuticals
KPRX
9 hedge funds and large institutions have $209K invested in Kiora Pharmaceuticals in 2022 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and 6 closing their positions.
300% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 1
6.6% less ownership
Funds ownership: 6.6% → 0% (-6.6%)
31% less funds holding
Funds holding: 13 → 9 (-4)
47% less capital invested
Capital invested by funds: $391K → $209K (-$182K)
67% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$121K |
| 2 |
Morgan Stanley
New York
|
+$20.5K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$12.3K |
| 4 |
SFM
Spartan Fund Management
Toronto, Ontario,
Canada
|
+$8.67K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$2.81K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$31K |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$24K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$22K |
| 4 |
Renaissance Technologies
New York
|
-$20K |
| 5 |
CAPTRUST Financial Advisors
Raleigh,
North Carolina
|
-$7K |
KPRX Hedge Fund Activity: Q3 2022 in Review
9 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Kiora Pharmaceuticals (KPRX) for Q3 2022, worth a combined $209K — down 47% from $391K a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of KPRX and 2 opened new positions — a net loss of 4 holders — while 1 trimmed existing stakes and 4 added.
The largest buyer was BlackRock, adding an estimated $121K. The largest seller was Vanguard Group, exiting entirely with an estimated $31K sold.
- 9 institutional investors held Kiora Pharmaceuticals (KPRX) as of Q3 2022, down from 13 in Q2 2022.
- Funds reported $209K of Kiora Pharmaceuticals stock for Q3 2022, down 47% quarter-over-quarter.
- 2 funds opened new Kiora Pharmaceuticals positions in Q3 2022 and 6 closed out, a net change of -4 holders.
- The largest Kiora Pharmaceuticals buyer in Q3 2022 was BlackRock, an estimated $121K added.
- The largest Kiora Pharmaceuticals seller in Q3 2022 was Vanguard Group, an estimated $31K sold.
Based on aggregated 13F filings for Q3 2022.